Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense
Award will support advancement of ALV-304 into the clinic for the potential treatment of inflammatory bowel disease Alivio Therapeutics, a biotechnology company developing an inflammation-targeting disease immunomodulation platform for the…